(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Rocket Pharmaceuticals's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast RCKT's revenue for 2025 to be $5,263,865,873, with the lowest RCKT revenue forecast at $1,185,042,105, and the highest RCKT revenue forecast at $10,291,634,897. On average, 4 Wall Street analysts forecast RCKT's revenue for 2026 to be $19,015,276,774, with the lowest RCKT revenue forecast at $677,297,142, and the highest RCKT revenue forecast at $40,136,191,054.
In 2027, RCKT is forecast to generate $25,358,077,905 in revenue, with the lowest revenue forecast at $1,673,644,081 and the highest revenue forecast at $49,042,511,730.